On a consolidated basis, the company reported net sales for the first quarter of $426 million and adjusted EBITDA of $54 million.
Based on that strong demand, we announced and began to implement price increases across our SBS product portfolio.
Collectively, this negatively impacted our adjusted Eva da by approximately $6.5 million are tissue business are lower orders and shipments reflecting overall market trends.
IRI market data showed a nearly 20% decline in overall tissue dollar sales in the first quarter of 2021.
As compared to the fourth quarter of 2020.
Let's discuss some additional details about both of our businesses.
Our sales and production volumes were slightly off due to the impact of the weather event in the south in February.
Our costs were elevated in part due to the weather events slightly offset by lower year over year input costs.
